Table of Contents
ISRN Infectious Diseases
Volume 2014, Article ID 378908, 6 pages
http://dx.doi.org/10.1155/2014/378908
Clinical Study

Targeted Screening for Latent TB Infection prior to Biologic Therapy to Improve Patient Safety and Reduce Costs: A Prospective Observational Study

1University of Glasgow Medical School Glasgow, UK
2Department of Rheumatology, Gartnavel General Hospital, Floor 7, 1053 Great Western Road, Glasgow G12 0YN, UK

Received 13 September 2013; Accepted 15 December 2013; Published 10 February 2014

Academic Editors: M. A. De Souza, L. Flores, and T. Matsumoto

Copyright © 2014 R. Hassanzadeh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. M. Arend and J. T. van Dissel, “Evidence of endogenous reactivation of tuberculosis after a long period of latency,” Journal of Infectious Diseases, vol. 186, no. 6, pp. 876–877, 2002. View at Google Scholar · View at Scopus
  2. U. Mack, G. B. Migliori, M. Sester et al., “LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement,” European Respiratory Journal, vol. 33, no. 5, pp. 956–973, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. W. G. Dixon, K. Watson, M. Lunt, K. L. Hyrich, A. J. Silman, and D. P. M. Symmons, “Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British society for rheumatology biologics register,” Arthritis & Rheumatism, vol. 54, no. 8, pp. 2368–2376, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. British Thoracic Society Standards of Care Committee, “British thoracic society recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment,” Thorax, vol. 60, no. 10, pp. 800–805, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. W. G. Dixon, K. L. Hyrich, K. D. Watson et al., “Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British society for rheumatology biologics register (BSRBR),” Annals of the Rheumatic Diseases, vol. 69, no. 3, pp. 522–528, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. S. D. Chakravarty, G. Zhu, M. C. Tsai et al., “Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs,” Infection and Immunity, vol. 76, no. 3, pp. 916–926, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. H. M. S. Algood, P. L. Lin, and J. L. Flynn, “Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis,” Clinical Infectious Diseases, vol. 41, no. 3, pp. S189–S193, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. M. Newton, S. L. Mackie, A. R. Martineau et al., “Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients,” Clinical and Vaccine Immunology, vol. 15, no. 3, pp. 506–512, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. J. C. Delgado, E. Y. Tsai, S. Thim et al., “Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 11, pp. 7576–7581, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Pai, A. Zwerling, and D. Menzies, “Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update,” Annals of Internal Medicine, vol. 149, no. 3, pp. 177–184, 2008. View at Google Scholar · View at Scopus
  11. R. Smith, A. Cattamanchi, K. R. Steingart et al., “Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders,” Current Opinion in Rheumatology, vol. 23, no. 4, pp. 377–384, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. S. S. Jick, E. S. Lieberman, M. U. Rahman, and H. K. Choi, “Glucocorticoid use, other associated factors, and the risk of tuberculosis,” Arthritis Care and Research, vol. 55, no. 1, pp. 19–26, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Gilham, J. France, A. Stirling, and S. Bawa, “Tuberculosis screening before biologics—T-SPOT for all?” The Journal of Rheumatology, vol. 38, no. 1, article 179, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Keane, S. Gershon, R. P. Wise et al., “Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent,” The New England Journal of Medicine, vol. 345, no. 15, pp. 1098–1104, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. A. K. Mohan, T. R. Coté, J. A. Block, A. M. Manadan, J. N. Siegel, and M. M. Braun, “Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor,” Clinical Infectious Diseases, vol. 39, no. 3, pp. 295–299, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. R. S. Wallis, “Tumour necrosis factor antagonists: structure, function, and tuberculosis risks,” The Lancet Infectious Diseases, vol. 8, no. 10, pp. 601–611, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Tubach, D. Salmon, P. Ravaud et al., “Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry,” Arthritis & Rheumatism, vol. 60, no. 7, pp. 1884–1894, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. National Institute for Health and Clinical Excellence, NICE Clinical Guideline 117—Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control, National Institute for Health and Clinical Excellence, 2011.
  19. L. Carmona, J. J. Gómez-Reino, V. Rodríguez-Valverde et al., “Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists,” Arthritis & Rheumatism, vol. 52, no. 6, pp. 1766–1772, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Beglinger, J. Dudler, C. Mottet et al., “Screening for tuberculosis infection before initiation of anti-TNF-α therapy,” Swiss Medical Weekly, vol. 137, no. 43-44, pp. 621–622, 2007. View at Google Scholar · View at Scopus
  21. Canadian Tuberculosis Committee (CTC), “Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An advisory committee statement (ACS),” Canada Communicable Disease Report, vol. 34, pp. 1–13, 2008. View at Google Scholar
  22. G. Ferrara, M. Losi, M. Meacci et al., “Routine hospital use of a new commercial whole blood interferon-γ assay for the diagnosis of tuberculosis infection,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 5, pp. 631–635, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. E. C. Keystone, K. A. Papp, and W. Wobeser, “Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists,” The Journal of Rheumatology, vol. 38, no. 7, pp. 1234–1243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Scharer and J. P. Smith, “Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid,” Annals of Internal Medicine, vol. 71, no. 6, pp. 1113–1120, 1969. View at Google Scholar · View at Scopus
  25. S. R. Salpeter, “Fatal isoniazid-induced hepatitis its risk during chemoprophylaxis,” Western Journal of Medicine, vol. 159, no. 5, pp. 560–564, 1993. View at Google Scholar · View at Scopus
  26. National Audit Office, Department of Health: Management of NHS Hospital Productivity, 2010, http://www.nao.org.uk/management-of-nhs-hospital-productivity.